{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T23:23:00Z","timestamp":1773184980217,"version":"3.50.1"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","funder":[{"name":"Internal Research Fund of the Saitama Children\u00e2\u20ac\u2122s Medical Center, Japan."}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Pediatric coronavirus disease (COVID-19)-associated encephalopathy can lead to severe neurologic complications. However, data comparing it with other infectious encephalopathies are limited. This study aimed to compare the clinical characteristics of COVID-19-associated encephalopathy with those of influenza-associated encephalopathy, which serves as a representative model of severe infectious encephalopathy in Japan. Additionally, we assessed the factors associated with a poor prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective cohort study of patients with COVID-19- and influenza-associated encephalopathy admitted to 7 children\u2019s hospitals in Japan between January 2017 and December 2023. Clinical characteristics were compared using the Mann\u2013Whitney\n                      <jats:italic toggle=\"yes\">U<\/jats:italic>\n                      test and Fisher exact test. Additionally, logistic regression analysis was performed to identify factors associated with a pediatric cerebral performance category score \u22654 at discharge.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 89 patients were included: 29 in the COVID-19 group and 60 in the influenza group. Demographics and initial clinical characteristics were similar between groups. However, a significantly higher proportion of patients in the COVID-19 group had a pediatric cerebral performance category score \u22654 at discharge (37.9% vs. 16.7%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.04). In each of the 3 separate multivariable models, COVID-19, the presence of underlying neurologic conditions and shorter time from onset to encephalopathy diagnosis were independently associated with poor prognosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The clinical characteristics of the 2 groups were similar; however, patients with COVID-19-associated encephalopathy showed worse discharge neurologic outcomes, warranting cautious interpretation. Enhancing public awareness of the severe outcomes and conducting further research is essential for better understanding its pathogenesis and treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000005040","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T05:00:45Z","timestamp":1762491645000},"page":"355-359","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Worse Neurologic Outcomes Observed in Pediatric COVID-19-associated Encephalopathy Than in Influenza-associated Encephalopathy"],"prefix":"10.1097","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8265-2448","authenticated-orcid":false,"given":"Haruka","family":"Takei","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases and Immunology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihoko","family":"Furuichi","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Immunology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenjiro","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Division of Neurology, Saitama Children\u2019s Medical Center, Saitama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikara","family":"Ogimi","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, National Center for Child Health and Development, Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Aichi"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munehiro","family":"Furuichi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Keio University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuto","family":"Otsubo","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Immunology, Department of Pediatrics, Tokyo Metropolitan Children\u2019s Medical Center, Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuo","family":"Motobayashi","sequence":"additional","affiliation":[{"name":"Division of Neuropediatrics, Nagano Children\u2019s Hospital, Nagano"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Chiba Children\u2019s Hospital, Chiba"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryohei","family":"Futatsugi","sequence":"additional","affiliation":[{"name":"Office for Infection Control, National Center for Child Health and Development, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eisuke","family":"Suganuma","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Immunology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"R2-20260310","doi-asserted-by":"crossref","first-page":"e2022058167","DOI":"10.1542\/peds.2022-058167","article-title":"COVID-19 and acute neurologic complications in children.","volume":"150","author":"Antoon","year":"2022","journal-title":"Pediatrics"},{"key":"R3-20260310","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s12519-022-00550-4","article-title":"COVID-19 and neurologic manifestations: a synthesis from the child neurologist\u2019s corner.","volume":"18","author":"Valderas","year":"2022","journal-title":"World J Pediatr"},{"key":"R4-20260310","doi-asserted-by":"crossref","first-page":"1085082","DOI":"10.3389\/fnins.2023.1085082","article-title":"Severe pediatric acute encephalopathy syndromes related to SARS-CoV-2.","volume":"17","author":"Sakuma","year":"2023","journal-title":"Front Neurosci"},{"key":"R5-20260310","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.3201\/eid3008.240031","article-title":"Fatal SARS-CoV-2 infection among children, Japan, January\u2013September 20221.","volume":"30","author":"Mitsushima","year":"2024","journal-title":"Emerg Infect Dis"},{"key":"R6-20260310","doi-asserted-by":"crossref","first-page":"122867","DOI":"10.1016\/j.jns.2024.122867","article-title":"Clinical characteristics of SARS-CoV-2-associated encephalopathy in children: nationwide epidemiological study.","volume":"457","author":"Kasai","year":"2024","journal-title":"J Neurol Sci"},{"key":"R7-20260310","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/INF.0b013e31816507b2","article-title":"Acute childhood encephalitis and encephalopathy associated with influenza: a prospective 11-year review.","volume":"27","author":"Amin","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"R8-20260310","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1086\/341407","article-title":"Encephalitis and encephalopathy associated with an influenza epidemic in Japan.","volume":"35","author":"Morishima","year":"2002","journal-title":"Clin Infect Dis"},{"key":"R9-20260310","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1093\/cid\/cix1126","article-title":"Characteristics and outcomes of influenza-associated encephalopathy cases among children and adults in Japan, 2010-2015.","volume":"66","author":"Okuno","year":"2018","journal-title":"Clin Infect Dis"},{"key":"R10-20260310","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.braindev.2011.07.012","article-title":"Epidemiology of acute encephalopathy in Japan, with emphasis on the association of viruses and syndromes.","volume":"34","author":"Hoshino","year":"2012","journal-title":"Brain Dev"},{"key":"R13-20260310","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1467-842X.2001.tb00294.x","article-title":"How can I deal with missing data in my study?","volume":"25","author":"Bennett","year":"2001","journal-title":"Aust N Z J Public Health"},{"key":"R14-20260310","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.brainres.2007.03.083","article-title":"\u201cTherapeutic time window\u201d duration decreases with increasing severity of cerebral hypoxia-ischaemia under normothermia and delayed hypothermia in newborn piglets.","volume":"1154","author":"Iwata","year":"2007","journal-title":"Brain Res"},{"key":"R15-20260310","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41409-022-01575-z","article-title":"Novel factors to predict respiratory viral disease progression in allogeneic hematopoietic cell transplant recipients.","volume":"57","author":"Ogimi","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"R17-20260310","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.virusres.2004.02.016","article-title":"Influenza-associated acute encephalopathy in Japanese children in 1994-2002.","volume":"103","author":"Togashi","year":"2004","journal-title":"Virus Res"},{"key":"R18-20260310","doi-asserted-by":"crossref","first-page":"1406874","DOI":"10.3389\/fmicb.2024.1406874","article-title":"COVID-19-associated encephalopathy: connection between neuroinflammation and microbiota-gut-brain axis.","volume":"15","author":"Duve","year":"2024","journal-title":"Front Microbiol"},{"key":"R19-20260310","doi-asserted-by":"crossref","first-page":"26331055231172522","DOI":"10.1177\/26331055231172522","article-title":"Mechanisms of SARS-CoV-2-induced encephalopathy and encephalitis in COVID-19 Cases.","volume":"18","author":"Vengalil","year":"2023","journal-title":"Neurosci Insights"},{"key":"R21-20260310","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1016\/j.vaccine.2022.04.033","article-title":"Trends in effectiveness of inactivated influenza vaccine in children by age groups in seven seasons immediately before the COVID-19 era.","volume":"40","author":"Shinjoh","year":"2022","journal-title":"Vaccine"},{"key":"R23-20260310","doi-asserted-by":"crossref","first-page":"116","DOI":"10.4103\/0974-777X.163102","article-title":"Does the influenza vaccine prevent sequelae such as myocarditis from developing?","volume":"7","author":"Whitney","year":"2015","journal-title":"J Glob Infect Dis"},{"key":"R24-20260310","doi-asserted-by":"crossref","first-page":"e2452512","DOI":"10.1001\/jamanetworkopen.2024.52512","article-title":"Estimated vaccine effectiveness for pediatric patients with severe influenza, 2015-2020.","volume":"7","author":"Sumner","year":"2024","journal-title":"JAMA Netw Open"},{"key":"R25-20260310","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/jmv.10088","article-title":"Prophylaxis and treatment of influenza encephalitis in an experimental mouse model.","volume":"67","author":"Shinjoh","year":"2002","journal-title":"J Med Virol"},{"key":"R26-20260310","doi-asserted-by":"crossref","first-page":"77","DOI":"10.15585\/mmwr.mm7304a2","article-title":"Early estimates of updated 2023\u20132024 (Monovalent XBB.1.5) COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection attributable to co-circulating omicron variants among immunocompetent adults\u2014increasing community access to testing program, United States, September 2023\u2013January 2024.","volume":"73","author":"Link-Gelles","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R28-20260310","doi-asserted-by":"crossref","first-page":"100528","DOI":"10.1016\/j.jvacx.2024.100528","article-title":"Factors influencing parental COVID-19 vaccination willingness for children in Japan.","volume":"19","author":"Ueta","year":"2024","journal-title":"Vaccine X"},{"key":"R29-20260310","doi-asserted-by":"crossref","first-page":"2296737","DOI":"10.1080\/21645515.2023.2296737","article-title":"Potential motivators affecting parental intention in COVID-19 vaccination for children aged 6 months to 4 years: Implications for targeted vaccine interventions in Japan.","volume":"19","author":"Kato","year":"2023","journal-title":"Hum Vaccin Immunother"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000005040","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T04:01:59Z","timestamp":1773115319000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000005040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000005040","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]}}}